Full-Time

Senior Manager Data Engineering

Posted on 8/29/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Data & Analytics (2)
,
Requirements
  • Doctorate degree / Master's degree / Bachelor's degree and 12 to 17 years Engineering, Computer Science, Data Science, Information Systems, or a related field
  • Minimum 8 years of experience in data engineering, analytics applications, and solution architecture, with demonstrable expertise in manufacturing data environments
  • Extensive experience architecting and delivering solutions using Databricks and AWS technology stacks for manufacturing data use cases
  • Proven leadership of global, multi-site engineering teams, including direct management, mentorship, and technical talent development
  • Strong background in the end-to-end software development lifecycle, including requirements gathering, technical product ownership, business analysis, and agile delivery
  • Experience implementing strategic digital transformation and driving innovation using scaled Agile and DevOps methodologies
  • Expertise with data pipeline development, ETL processes, job scheduling, monitoring, and incident management across cloud and on-premises platforms
  • Deep understanding of GxP, validation, data privacy, and compliance requirements for pharmaceutical and biotechnology manufacturing environments
  • Demonstrated proficiency in Python, SQL, and/or other relevant programming languages for data engineering and analytics automation
  • Strong knowledge of AI/ML concepts and their practical application to manufacturing analytics (predictive analytics, anomaly detection, root cause analysis, etc.)
  • Outstanding communication and collaborator engagement skills across all levels, including executive leadership
  • Experience managing budgets, vendor relationships, and external partnerships
Responsibilities
  • Team Leadership: Manage and mentor a team of data scientists and data engineers, fostering a culture of technical excellence, collaboration, innovation, and continuous improvement.
  • Agile Product Delivery: Oversee multiple agile product teams developing and maintaining manufacturing data and analytics applications used at Amgen’s global manufacturing sites. Ensure seamless integration of agile ways of working, and drive delivery of high-quality, scalable solutions.
  • Data Pipeline Development: Lead design, implementation, and optimization of data pipelines enabling ingestion, validation, transformation, and publishing of data across cloud and on-premises systems, with a focus on Databricks and AWS.
  • Manufacturing Data Expertise: Ensure solutions are tailored to manufacturing data use cases, including process optimization, predictive maintenance, quality analytics, and regulatory compliance.
  • Collaboration & Collaborator Engagement: Partner with Digital, Technology & Innovation, Operations, Quality, IT, Automation, and Data Science leaders to align operational priorities and ensure solutions meet evolving business needs.
  • Governance & Compliance: Drive adherence to data quality, privacy, GxP regulations, and audit readiness. Collaborate with governance, compliance, and security teams to maintain regulatory alignment and standard methodologies.
  • Technology Strategy: Evaluate, adopt, and guide the lifecycle management of emerging technologies (Databricks, AWS, data lakes, AI/ML, containerization) to enhance analytics capabilities for advanced manufacturing use cases.
  • Incident Management & Root Cause Analysis: Serve as the partner concern point for data-related and application incidents, ensuring timely resolution, root cause analysis, and continuous improvement.
  • Vendor & External Partnerships: Manage external partnerships, budget, and resources to support strategic objectives and drive optimal performance of data platforms and analytics solutions.
  • Documentation & Knowledge Sharing: Oversee comprehensive documentation, training, and knowledge management programs to support team development and global adoption of manufacturing data applications.
  • Change Management: Champion change management strategies to embed data-driven thinking, analytics adoption, and agile methodologies at all organizational levels.
  • Representation: Represent Amgen’s Manufacturing Data Engineering strategy, practices, and results to senior leadership, regulatory agencies, and external technology partners as required.
Desired Qualifications
  • Doctorate in Computer Science, Engineering, Life Sciences, or related technical discipline
  • Certification in Databricks and AWS Data Engineering/Architecture
  • Expertise in manufacturing data platforms such as OSIsoft PI/AVEVA, batch reporting systems, and integration with MES, SAP, and automation platforms
  • Experience with advanced analytics visualization tools (Power BI, Tableau, Spotfire) and their integration with manufacturing data sources
  • Deep understanding of ISA-95 and ISA-88 manufacturing standards
  • Hands-on experience with cloud-based analytics, data lakes, data fabrics, and containerization (Kubernetes)
  • Applied knowledge of DevOps practices, automated testing, and continuous integration/deployment
  • Domain expertise in health or life sciences, with a focus on manufacturing operations
  • Proficiency with graph databases, semantic modeling, and data science toolkits (R, Python, Oracle)
  • Experience driving a collaborative, customer-focused culture that values technical depth, accountability, and service excellence
  • Soft Skills: Visionary leadership with a passion for nurturing technical talent and building high-performing analytics teams
  • Soft Skills: Strategic thinking and adaptability in leveraging data and analytics in manufacturing
  • Soft Skills: Exceptional organizational, problem-solving, and analytical skills
  • Soft Skills: Resilience and composure in dynamic, fast-paced global environments
  • Soft Skills: Commitment to diversity, inclusion, and fostering a collaborative, data-centric culture
  • Soft Skills: Excellent verbal and written communication; strong presentation and public speaking abilities
  • Soft Skills: High degree of initiative, motivation, and team orientation focused on achieving team goals

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE